STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,286,547)	$ (16,910,533)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	513,028	485,710
Share-based payments for services	688,070	349,319
Share-based payments for interest	0	80,716
Equity based compensation	2,626,311	2,193,402
Common stock contributed to 401(k) plan	108,485	109,073
Shares issued for settlement of clinical research costs	1,290,000	2,957,400
Loss on prepaid research and development	0	471,157
Loss (gain) on derivative instruments	3,316,384	(187,967)
Amortization of debt discount	0	1,956,424
Inducement expense	0	291,234
Capitalized lease interest	95,742	125,044
(Increase)/decrease in assets:
Receivables	393	98,829
Prepaid expenses	11,047	122,627
Inventory used for R&D and manufacturing	(109,587)	44,364
Deposits	0	150,000
Increase/(decrease) in liabilities:
Accounts payable	(3,567,182)	(1,960,438)
Accrued expenses	(113,280)	(74,856)
Due to employees	(3,914)	548,982
Other liabilities	(2,544)	4,819
Net cash used in operating activities	(12,433,594)	(9,144,694)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(171,321)	(1,015)
Expenditures for patent costs	(115,476)	(2,437)
Net cash used in investing activities	(286,797)	(3,452)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	0	7,091,536
Payments of stock issuance costs	(90,224)	(94,773)
Proceeds from exercise of warrants	11,657,590	2,133,677
Proceeds from exercise of options	97,290	0
Proceeds from the purchase of stock by officers and directors	234,997	0
Payments on obligations under capital lease	(3,811)	(5,082)
Net cash provided by financing activities	11,895,842	9,125,358
NET DECREASE IN CASH AND CASH EQUIVALENTS	(824,549)	(22,788)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,310,044	2,369,438
CASH AND CASH EQUIVALENTS, END OF PERIOD	9,485,495	2,346,650
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capitalizable patent costs included in current liabilities	30,000	61,501
Capital lease obligation included in accounts payable	434	408
Exercise of derivative liabilities	1,900,618	784,119
Stock issuance costs included in current liabilities	8,010	0
Prepaid consulting services paid with issuance of common stock	(119,791)	113,786
Notes payable converted into common shares	0	2,294,300
Cash paid for interest expense	$ 1,355,676	$ 1,312,664